Citi Pharma Ltd
Citi Pharma Ltd operates in Pharmaceuticals.
Citi Pharma Ltd (CPHL) - Net Assets
Latest net assets as of : PKRs- PKR
Based on the latest financial reports, Citi Pharma Ltd (CPHL) has net assets worth PKRs- PKR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (PKRs-) and total liabilities (PKRs-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | PKRs- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Citi Pharma Ltd - Net Assets Trend (None–None)
This chart illustrates how Citi Pharma Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Citi Pharma Ltd (None–None)
The table below shows the annual net assets of Citi Pharma Ltd from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to Citi Pharma Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Citi Pharma Ltd Competitors by Market Cap
The table below lists competitors of Citi Pharma Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SOUTH BOULDER MINES
MU:SO3
|
$2.41K |
|
Iargento Hi Tech Assets Limited Partnership
TA:IARG
|
$2.42K |
|
Creightons Plc
LSE:CRL
|
$2.42K |
|
Atlantis Resources Ltd
LSE:SAE
|
$2.42K |
|
UTENOS TRIKOTAZAS (UD5.SG)
STU:UD5
|
$2.40K |
|
UF Games S.A.
WAR:UFG
|
$2.40K |
|
Advanced Graphene Products S.A.
WAR:GPH
|
$2.40K |
|
SEEDCO INTERNATIONAL LIMITED
XBOT:SEED-EQO
|
$2.40K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Citi Pharma Ltd's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Citi Pharma Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Citi Pharma Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares Citi Pharma Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $17,227,128,333
- Average return on equity (ROE) among peers: 15.71%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Citi Pharma Ltd (CPHL) | PKRs- | N/A | N/A | $2.41K |
| Abbott Laboratories Pakistan Ltd (ABOT) | $13.24 Billion | 20.36% | 0.53x | $31.06K |
| AGP Ltd (AGP) | $12.36 Billion | 12.66% | 1.26x | $6.39K |
| The Searle Company Ltd (SEARL) | $26.09 Billion | 14.10% | 0.88x | $2.95K |